Nivolumab and relatlimab for first-line treatment of unresectable or metastatic melanoma

Published on 05 Oct 2026
Last Updated on 05 Oct 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended nivolumab and relatlimab fixed-dose combination (FDC) for inclusion on the MOH List of Subsidised Drugs for first-line treatment of unresectable or metastatic melanoma. The decision was based on the uncertain extent of clinical benefit and inferior safety compared with nivolumab monotherapy. The nivolumab and relatlimab FDC is also unlikely to represent an acceptable use of healthcare resources, and the price-volume agreement proposed by the company was unacceptable.

Clinical indication, subsidy class and MediShield Life claims eligibility for nivolumab and relatlimab FDC are provided in the Annex.

Nivolumab and relatlimab for first-line treatment of unresectable or metastatic melanoma (Published 05 Oct 2026) [PDF, 353.74 KB] (opens in new tab)

Plain English Summary

Melanoma is a type of skin cancer that begins in melanocytes, the cells that give skin its colour. It often develops on parts of the skin that have had a lot of sun exposure. In the early stages, melanoma can often be removed with surgery. If the melanoma cannot be removed by surgery, this is known as unresectable melanoma. If it spreads to other parts of the body, this is known as metastatic disease.

Nivolumab and relatlimab are biologic medicines known as monoclonal antibodies. They work by blocking certain proteins that can prevent immune cells from recognising and attacking cancer cells. Nivolumab and relatlimab are combined in a single medicine called a fixed-dose combination (FDC) and given as a slow drip into a vein (infusion).

Nivolumab and relatlimab FDC was not recommended for government funding because its benefits do not justify its cost compared with alternative treatments. It is not subsidised and cannot be claimed under MediShield Life.

There are different treatments available for unresectable or metastatic melanoma. Your doctor can advise whether nivolumab and relatlimab FDC or other treatments may be suitable for you.